PAA are managing it precisely like another stock I am in - BOT. BOT have a pipeline of Ph2/3 drugs for acne, rosacea, and anti-microbial, but their sole focus is on one product for axillary hyperhidrosis. That's where they are focusing all of their money and energy. That is the quickest path to either a takeover or become a revenue-producing company.
Exactly the same with PAA. Nothing is 'lost' - but the smart business move is to put all of their time, energy and money toward MPL. That is the quickest path to either a takeover or become a revenue-producing company.
Ann: Investor Briefings & Webinar Notice, page-36
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.69M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.3¢ | $108.2K | 647.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 109170 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 117939 | 4 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |